Health Economic Assessment for Screening of Gastric Cancer in A High Risk Population in Northeastern China
查看参考文献18篇
|
文摘
|
Objective: To assess economic cost‐effects for the screening programs of gastric cancer in a high risk population in northeastern China. Methods: The data were collected from November 2001 to December 2003. The multi‐stage sampling to define the screening group and the control group was applied in this study. Two stage screening programs were used in the study. An epidemiological survey and serum PG test were carried out in the first stage. The endoscopy and pathological examination were performed in the second stage screening. Effectiveness was assessed by the increased quality adjusted life‐year (QALY) because of reduced gastric cancer deaths in screening. Results: A total of 27,970 participants (n=7,128 screening group, n=20,842 control group) were enrolled in the survey. Twenty nine gastric cancer cases were detected in the screening group with 20 cases in the early stage and 9 cases in the advanced stage, respectively. Eighty six gastric cancer cases were detected in the control group, all of whom were in the advanced stage and had died before the study finished. The screening and treatment of 29 cases cost $152,227 and $5,249 per each case, respectively. The costs were $459 to gain per QALY. Conclusion: The screening program of gastric cancer used in our study is an economic and society‐beneficial measure to detect gastric cancer in high risk area. The methods fit China's present economic development level |
|
来源
|
Chinese Journal of Cancer Research
,2011,23(1):21-24 【核心库】
|
|
关键词
|
Gastric cancer
;
Screening
;
Economics
|
|
地址
|
1.
Department of Epidemiology, School of Public Health,China Medical University, Shenyang, 110001
2.
Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, 110001
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-9604 |
|
学科
|
肿瘤学 |
|
基金
|
National Key Technologies R&D Program of China during the 10th Five‐year Plan Period
|
|
文献收藏号
|
CSCD:4173891
|
参考文献 共
18
共1页
|
|
1.
Crew KD. Epidemiology of gastric cancer.
World J Gastroenterol,2006,12:354-362
|
CSCD被引
90
次
|
|
|
|
|
2.
Parkin DM. International variation.
Oncogene,2004,23:6329-6340
|
CSCD被引
34
次
|
|
|
|
|
3.
Ferlay J.
GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide,2004
|
CSCD被引
6
次
|
|
|
|
|
4.
National Comprehensive Cancer Network.
Clinical practice guidelines in oncology: Gastric Cancer,2007
|
CSCD被引
1
次
|
|
|
|
|
5.
Chen XM. Detection of micrometastasis of gastric carcinoma in peripheral blood circulation.
World J Gastroenterol,2004,10:804-808
|
CSCD被引
8
次
|
|
|
|
|
6.
Kikuchi S. Survival after surgical treatment of early gastric cancer: surgical techniques and long‐term survival.
Langenbecks Arch Surg,2004,389:69-74
|
CSCD被引
7
次
|
|
|
|
|
7.
Onodera H. Surgical out‐come of 483 patients with gastric cancer: prognosis, postoperative morbidity and mortality, and gastric remnant cancer.
Hepatogastroenterology,2004,51:82-85
|
CSCD被引
4
次
|
|
|
|
|
8.
Kim JP. Clinical analysis of early gastric cancer.
Korean J Gastroenterol,1991,23:428-435
|
CSCD被引
1
次
|
|
|
|
|
9.
Leung WK. Screening for gastric cancer in Asia: current evidence and practice.
Lancet Oncol,2008,9:279-287
|
CSCD被引
71
次
|
|
|
|
|
10.
Guo HQ. The Initial Epidemiological Evaluation to Comprehensive Prevention to Gastric Carcinoma.
Chin J Health Stat (in Chinese),2001,18:69-73
|
CSCD被引
1
次
|
|
|
|
|
11.
Guo HQ. Prospective cohort study of comprehensive prevention to gastric cancer.
World J Gastroenterol,2003,9:432-436
|
CSCD被引
7
次
|
|
|
|
|
12.
Yuan Y. Comprehensive Prevention and Treatment for High Risk Population in High Risk Area with Gastric Cancer in Zhuanghe Region, Liaoning Province.
Bull Chin Cancer (in Chinese),2005,14:307-311
|
CSCD被引
3
次
|
|
|
|
|
13.
Miki K. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects.
Jpn J Cancer Res,1989,80:111-114
|
CSCD被引
5
次
|
|
|
|
|
14.
Yoshida S. Detection and treatment of early cancer in high‐risk populations.
Best Pract Res Clin Gastroenterol,2006,20:745-765
|
CSCD被引
5
次
|
|
|
|
|
15.
Ramsey S. Gut check: can cost‐effectiveness analysis help eliminate gastric cancer.
Asia Cancer Epidemiol Biomarkers Prev,2007,16:873-874
|
CSCD被引
1
次
|
|
|
|
|
16.
Dinis‐Ribeiro M. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow‐up of patients at risk for intestinal‐type gastric adenocarcinoma.
Neoplasia,2004,6:449-456
|
CSCD被引
1
次
|
|
|
|
|
17.
Broutet N. Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics.
Br J Cancer,2003,88:1239-1247
|
CSCD被引
18
次
|
|
|
|
|
18.
Kikuchi S. Long‐term effect of Helicobacter pylori infection on serum pepsinogens.
Jpn J Cancer Res,2000,91:471-476
|
CSCD被引
1
次
|
|
|
|
|
了解气象卫星更多信息，请访问